Italia markets closed

Dow Jones
39.994,10
-9,49(-0,02%)
Nasdaq
16.812,10
+126,13(+0,76%)
Nikkei 225
39.069,68
+282,30(+0,73%)
EUR/USD
1,0868
-0,0004(-0,03%)
Bitcoin EUR
62.735,92
+1.259,04(+2,05%)
CMC Crypto 200
1.380,49
+26,07(+1,93%)

NVCR Dec 2025 22.500 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

3,8000

0,0000

(0,00%)

In data: 12:04PM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in